SCHEMBL3217657

SCHEMBL3217657

O=C(O)NS(=O)(=O)NCCc1cccs1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
TAAR1 Q96RJ0 1/20 0.46
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
POLB P06746 3/20 0.43
HSD11B1 P28845 1/20 0.43
CYP2C19 P33261 1/20 0.42
ADAM17 P78536 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7263003 0.79 NPC1 (0.53) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL2731878 0.77 NPC1 (0.68) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL3208037 0.76 TAAR1 (0.50) NPC1RAB9ASMN1; SMN2TAAR1LMNA
Acetic Acid SCHEMBL27263112 0.75 LMNA (0.53) SMN1; SMN2LMNAMEN1KMT2APOLB
SCHEMBL6564813 0.75 TDP1 (0.56) SMN1; SMN2TAAR1LMNAMEN1KMT2A
SCHEMBL10689007 0.74 CYP19A1 (0.48) NPC1RAB9ASMN1; SMN2LMNAMEN1
SCHEMBL4600838 0.74 NPC1 (0.48) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL12601569 0.72 SMN1; SMN2 (0.45) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL2840589 0.72 CA1 (0.48) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL5574088 0.72 ALDH1A1 (0.60) NPC1RAB9ASMN1; SMN2LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 NPC1 1683/4885RAB9A 3599/4885SMN1; SMN2 3845/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 NPC1 1377/4885RAB9A 3729/4885SMN1; SMN2 4093/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 NPC1 1683/4885RAB9A 3599/4885SMN1; SMN2 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.